Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance
2021 · British Journal of Cancer · 41 citations
https://doi.org/10.1038/s41416-020-01240-6
B
Bo Ma
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
125
Papers
3.0K
Citations
26
h-index
51
i10-index
Bo Ma is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Cancer Cells and Metastasis & Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers. The author has an h-index of 26, co-authored 107 publications.
ORCID: 0000-0003-0816-6630Papers by this author
worksCharacterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer
2021 · Molecular Therapy — Oncolytics · 38 citations
https://doi.org/10.1016/j.omto.2021.06.011
DIP2C expression in breast cancer and its clinical significance
2017 · Pathology - Research and Practice · 19 citations
https://doi.org/10.1016/j.prp.2017.09.007
ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer.
2015 · PubMed · 18 citations
Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis
2024 · Oncogene · 13 citations
https://doi.org/10.1038/s41388-024-03237-4
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
2025 · Journal for ImmunoTherapy of Cancer · 10 citations
https://doi.org/10.1136/jitc-2024-010565
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat